Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Wall Street Zen

Palisade Bio (NASDAQ:PALI) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a note issued to investors on Saturday.

Several other analysts also recently weighed in on PALI. Citigroup reiterated a “buy” rating on shares of Palisade Bio in a research note on Tuesday, November 11th. Piper Sandler assumed coverage on Palisade Bio in a research report on Monday, December 29th. They issued an “overweight” rating and a $25.00 target price on the stock. Clear Str upgraded shares of Palisade Bio to a “strong-buy” rating in a report on Monday, December 29th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Palisade Bio in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $20.50.

Palisade Bio Trading Up 6.4%

Shares of Palisade Bio stock opened at $2.50 on Friday. The firm’s 50 day simple moving average is $2.01 and its two-hundred day simple moving average is $1.33. The firm has a market capitalization of $372.50 million, a price-to-earnings ratio of -1.18 and a beta of 1.43. Palisade Bio has a 12-month low of $0.53 and a 12-month high of $2.64.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.06). On average, sell-side analysts predict that Palisade Bio will post -12.43 EPS for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.